title: T cell-mediated acute localized exanthematous pustulosis caused by finasteride.
abstract: A 21-year-old man presented with multiple erythematous nonfollicular papules partially confluent to plaques on his breast and lower abdomen that had been present for 1 month. Grouped pustules were present under the right breast. The patient had been taking finasteride over the past 3 months for androgenetic alopecia. His medical history was negative for psoriasis. Our initial differential diagnosis included dyskeratosis follicularis Darier, allergic contact dermatitis, infectious folliculitis, varicella zoster virus infection, fixed drug eruption, and IgA pemphigus. The white blood cell count and differential were within the normal limits. Results of viral cultures and PCR, as well as bacterial and fungal cultures of skin lesions proved negative. A lesional biopsy specimen showed a slight psoriasiform acanthosis in association with spongiosis and infiltration of both the epidermis and dermis by neutrophils and eosinophils, resulting in formation of subcorneal, intraepidermal, and subepidermal pustules. The results of direct immunofluorescence were negative, excluding an IgA pemphigus. The result of a lymphocyte transformation test was positive for finasteride. On the basis of the time relationship between the administration of finasteride and the development of the skin disease in combination with symptoms resolution on cessation of the drug, the histologic findings, and the positive lymphocyte transformation test result, we consider this to be an unusual type of acute generalized exanthematous pustulosis defined as acute localized exanthematous pustulosis caused by finasteride. Within 4 weeks after withdrawal of finasteride, the rash resolved without any specific therapy. Transient discrete residual hyperpigmentation and scaling were present. The patient refused an oral provocation challenge.
authors.affiliation: Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
authors.forename: Sandra
authors.initials: S
authors.lastname: Tresch
authors.forename: Antonio
authors.initials: A
authors.lastname: Cozzio
authors.forename: Jivko
authors.initials: J
authors.lastname: Kamarashev
authors.forename: Thomas
authors.initials: T
authors.lastname: Harr
authors.forename: Peter
authors.initials: P
authors.lastname: Schmid-Grendelmeier
authors.forename: Lars E
authors.initials: LE
authors.lastname: French
authors.forename: Laurence
authors.initials: L
authors.lastname: Feldmeyer
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000009:adverse effects*; D056150:Acute Generalized Exanthematous Pustulosis / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D000328:Adult; D000505:Alopecia / Q000188:drug therapy; D018120:Finasteride / Q000009:adverse effects*; D006801:Humans; D008213:Lymphocyte Activation; D008297:Male; D013601:T-Lymphocytes / Q000276:immunology; D055815:Young Adult
chemical_list: D058891:5-alpha Reductase Inhibitors; D018120:Finasteride